. Tight junctions are dynamic structures, and their permeability is regulated by several physiological mechanisms, including phosphorylation of myosin light chain (MLC) II by MLC kinase (MLCK) (27) . This process is known to stimulate contraction of perijunctional actin, therefore inducing distension of individual tight junction strands and an increase in paracellular permeability (57) .
Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), is characterized by chronic inflammation of the GI tract. While the etiology of IBD remains incompletely understood, loss of epithelial barrier function is hypothesized to play an important role in the pathogenesis of the disease; several studies have revealed structural abnormalities in apical junctional complexes in IBD patients, including downregulation of ZO-1, occludin, claudin-1, and adherens junction proteins E-cadherin and ␣-catenin (13, 20, 26, 29, 49) . IBD is associated with a massive accumulation of neutrophils (PMNs) in the intestinal mucosa. The subsequent transmigration of these PMNs across the epithelium into the intestinal lumen has been shown to require remodeling of apical junctional complexes and is believed to participate in tissue damage and ulceration in the context of IBD (16, 29, 40, 46) . IL-18, originally referred to as IFN␥-inducing factor, is a member of the IL-1 cytokine family. In the gut mucosa, IL-18 is primarily released by macrophages, dendritic cells, and intestinal epithelial cells (24, 39, 48) . Previous studies demonstrated elevated levels of IL-18 in the mucosa of UC and CD patients (32, 35, 39, 48) , where it is believed to synergize with IL-12 to induce a strong Th1 response, thereby contributing to mucosal inflammation and tissue damage (50) . An imbalance between IL-18 and its endogenous inhibitor, the IL-18-binding protein, is also believed to contribute to overt inflammation in the context of IBD (32) . Notably, immunological neutralization or targeted gene deletion of IL-18 was shown to reduce disease severity in several murine models of colitis (25, 54 -56, 59) , lending further support to the hypothesis that IL-18 plays a role in the pathophysiology of IBD.
The aims of the present study were to determine the effects of IL-18 on epithelial tight junction structure and function and to investigate the mechanism involved in this process. Our findings indicate that IL-18 facilitates PMN transepithelial migration via MLCK-dependent disruption of tight junctional occludin, without altering epithelial permeability.
MATERIALS AND METHODS
Cell culture. Human colonic epithelial (Caco-2) cells (American Type Culture Collection, Manassas, VA) were cultured in minimum essential medium Eagle's (MEME; Sigma, St. Louis, MO) supple-mented with 20% heat-inactivated (HI) FBS, 100 g/ml streptomycin, 100 U/ml penicillin, 1 mM sodium pyruvate, and 2 mM L-glutamine (all from Sigma). Cells were kept at 37°C with 5% CO 2 in 96% humidity. Culture medium was replenished every 2-3 days. Cells were subcultured every 6 -8 days with 2ϫ trypsin-EDTA (Sigma) and grown to confluence on Lab-Tek chamber slides (Nalge Nunc, Naperville, IL), culture-treated plates (Becton Dickinson, Sparks, MD), or Transwell filter units with semipermeable filter membranes (0.4-to 3.0-m pores; Costar, Cambridge, MA). Caco-2 cells were used at passages 24 -34 . At the time of treatment, Caco-2 monolayers were incubated in 5% HI-FBS MEME.
Reagents, inhibitors, and antibodies. Caco-2 monolayers were incubated apically (unless otherwise specified) with purified recombinant human IL-18 (50 ng/ml; R & D Systems, Minneapolis, MN) for 24 h (28, 33) . For some experiments, the selective MLCK inhibitor ML9 (40 M; Sigma) (17, 57) or the NF-B inhibitor BAY 11-7082 (5 M; EMD Chemicals, Mississauga, ON, Canada) (36, 47) was added 1 h prior to IL-18 treatment and remained in the medium throughout the treatment period.
The following antibodies were used for immunocytochemistry and/or immunoblotting: rabbit monoclonal anti-occludin, mouse monoclonal anti-occludin, and anti-ZO-1 (1:1,000 dilution; all from Invitrogen, Carlsbad, CA);, rabbit monoclonal anti-claudin-4 and -claudin-5 (1:200 dilution; both from Thermo Fisher Scientific, Fremont, CA); mouse monoclonal anti-E-cadherin (1:1,000 dilution) and anti-CD11b/Mac-1 (1:4,000 dilution; both from BD Biosciences, Mississauga, ON, Canada); rabbit polyclonal anti-MLC and mouse monoclonal anti-phosphorylated MLC II (1:1,000 dilution; both from Cell Signaling Technology, Danvers, MA); and rabbit polyclonal anti-MLCK (1:500 dilution) and mouse monoclonal anti-GAPDH (1:1,000 dilution; both from Sigma). Mouse or rabbit horseradish peroxidaseconjugated secondary antibodies (1:1,000 dilution; both from Cell Signaling Technology) were used for Western blotting. Anti-mouse Alexa Fluor 555-, anti-rabbit Alexa Fluor 555-, and anti-mouse Alexa Fluor 488-conjugated secondary antibodies (1:1,000 dilution; all from Invitrogen) were used for immunocytochemistry.
Immunofluorescence microscopy. Cell monolayers grown on LabTek chamber slides were washed twice with PBS and fixed/permeabilized in cold methanol for 30 min at 4°C. Nonspecific binding was blocked with HI-FBS for 15 min at room temperature, and the monolayers were incubated with primary antibodies for 1 h at 37°C. Cells were then washed with PBS three times, incubated with the appropriate secondary antibody for 1 h at 37°C, and mounted with Aqua PolyMount (Polysciences, Warrington, PA). Epifluorescent images were taken with a Leica DMR fluorescence microscope and Retiga 2000R camera (Q Imaging, Surrey, BC, Canada) and analyzed with Velocity (Improvision, Waltham, MA). Confocal images were taken with a fluorescence microscope (model 510) and AxioCam HRm camera and analyzed with LSM510 Meta (all from Zeiss, Toronto, ON, Canada). Images are representative micrographs of four replicate monolayers in each of three separate experiments.
Whole cell protein extraction. Cell monolayers grown on six-well plates were washed twice with PBS and lysed for 30 min at 4°C with 150 l of RIPA buffer (1ϫ PBS, 1% Igepal CA-630, 0.5% sodium deoxycholate, and 0.1% SDS; all from Sigma) containing a protease inhibitor tablet (Complete-Mini, Roche Diagnostics, Laval, QC, Canada). Lysates were sonicated for 5 s and centrifuged at 10,000 g for 10 min. Supernatants were collected, and protein concentrations were quantified using a Bradford assay (Bio-Rad Laboratories, Hercules, CA). Protein concentration was normalized to 3 mg/ml, and samples were diluted 1:1 in 2ϫ electrophoresis buffer and boiled for 5 min. Sample aliquots were stored at Ϫ20°C until use.
Immunoblotting. Samples were separated by SDS-PAGE (7-15%) and transferred to nitrocellulose membranes (Whatman, Buckinghamshire, UK). Membranes were blocked in 5% nonfat dry milk in Tris-buffered saline (TBS) ϩ 0.1% Tween (TBS-T) for 1 h and probed with primary antibodies (diluted in 5% milk TBS-T) for 1 h at room temperature. Membranes were then washed three times with TBS-T and incubated with the appropriate horseradish peroxidaseconjugated secondary antibody (diluted in 5% milk-TBS-T) for 1 h at room temperature. Bands were visualized using the ECL-plus chemiluminescence detection system (GE Healthcare, Pittsburgh, PA), and band density was calculated using ImageJ densitometry software (http://rsbweb.nih.gov/ij/). GAPDH was used as a loading control.
RNA isolation and gene expression analysis. Reverse transcription and quantitative real-time PCR (qPCR) were performed as previously described (31) . Briefly, total RNA was extracted from cells with an RNeasy kit (Qiagen, Mississauga, ON, Canada), and first-strand cDNA was synthesized using the SuperScript First-Strand Synthesis System (Invitrogen) according to the manufacturer's instructions. Levels of specific mRNA transcripts were determined by qPCR using SYBR Green PCR Master Mix and an iCycler real-time PCR detection system (Bio-Rad Laboratories). Relative levels of mRNA transcripts were calculated using individual standard curves and normalized to relative GAPDH mRNA levels. The following primers were used: occludin [CAGGGAATATCCACCTATCACTTCAG and CATCAG-CAGCAGCCATGTACTCTTCAC (4) Transepithelial resistance. Caco-2 cells were grown to confluence (Ͼ500 ⍀·cm 2 ) on Transwell filter units (0.4-m pore size) and treated according to experimental design. Transepithelial resistance was measured using an electrovoltohmeter (World Precision Instruments, Sarasota, FL).
Dextran flux. Transepithelial permeability to an FITC-dextran 3-kDa probe (Invitrogen) was assessed as previously described (17) . Briefly, Caco-2 cell monolayers were grown to confluence on Transwell filter units (0.4-m pore size) and treated according to experimental design. After treatment, apical and basolateral cell compartments were washed twice with 37°C sterile bicarbonate buffer-Ringer solution [115 mM NaCl, 50 mM NaHCO3, 2.8 mM KH2PO4, 1.2 mM CaCl2, 1.2 mM MgCl2, and 10 mM glucose (pH 7.4); all from Sigma]. The nonabsorbable probe (500 l; 100 M in Ringer solution) was added to the apical compartment, and 1 ml of Ringer solution was added to the basolateral compartment. Transepithelial passage of the probe was used as a direct indicator of paracellular permeability. After a 3-h incubation period (37°C, 5% CO2, 96% humidity), two 300-l samples were taken from the basolateral compartment of each chamber, and relative fluorescence was calculated using a microplate reader (SpectraMax M2 e , Molecular Devices, Sunnyvale, CA). Values were expressed as basolateral FITC-dextran relative to untreated controls.
Bacterial culture and translocation assay. Translocation of nonpathogenic, noninvasive Escherichia coli C25 was used as another maker of paracellular permeability, as validated previously (30) . Streptomycin-resistant E. coli C25 was grown from a 10% glycerol frozen stock in MacConkey broth (Becton Dickinson), at 37°C for 6 h on a shaker (150 rpm). Bacterial concentrations were estimated using optical density readings (600 nm) and confirmed by colonyforming unit enumeration on MacConkey agar (Becton Dickinson).
Caco-2 cell monolayers were grown to confluence on Transwell filter units (3.0-m pore size) and treated with IL-18 in antibiotic-free 5% HI-FBS MEME. After 24 h, monolayers were inoculated apically with log-phase E. coli C25 (100:1 multiplicity of infection) and incubated at 37°C (5% CO2, 96% humidity) for 3 h; then the basolateral medium was serially diluted, and E. coli was enumerated as described above.
PMN isolation and transmigration. Blood was obtained according to standard techniques from healthy volunteers in accordance with protocols approved by the University of Calgary. Human PMNs were isolated by dextran sedimentation and Percoll density-gradient separation, as previously described (14) . Briefly, blood was collected in acid-citrate-dextrose Vacutainers (Becton Dickinson), pooled, and centrifuged at 350 g for 20 min. The platelet-rich plasma was discarded, and leukocytes were separated from erythrocytes by dextran (0.6%) sedimentation (Sigma). The leukocyte-rich upper layer was fractionated using isotonic Percoll (Sigma). PMNs were finally harvested from the 70%-81% interface and washed twice in Hanks' balanced saline solution (HBSS) without Ca 2ϩ (HBSSϪ). Cell viability was assessed by trypan blue (Invitrogen) exclusion, and PMNs were enumerated on a hemocytometer.
Transmigration assays were performed with inverted Caco-2 cell monolayers grown on collagen-coated Transwell filter units (3.0-m pore size), as previously described (34) . After the cells were allowed to adhere overnight, Transwell inserts were inverted and inserted into 24-well plates. Five hundred microliters of cell medium were added to the lower compartment (apical surface) and 100 l to the upper compartment (basolateral surface). Cells were grown to confluence and treated according to experimental design. After treatment, apical and basolateral compartments were washed twice with HBSS containing Ca 2ϩ (HBSSϩ) and allowed to recover in HBSSϩ for 30 min. The upper compartment was then filled with 100 l of HBSSϩ, and the lower compartment was filled with 500 l of HBSSϩ containing 1 M fMLP (a PMN chemoattractant; Sigma). The PMN transmigration assay was then initiated by addition of 20 l of HBSSϪ containing 1 ϫ 10 6 PMNs to the upper compartment of each well. Plates were incubated at 37°C (5% CO2, 96% humidity) for 1-2 h; then the apical chamber's supernatants were collected, and transmigrated apical PMNs were stained with trypan blue and counted on a hemocytometer. Results were expressed as number of PMNs recovered from the apical chamber. Occludin alterations associated with IL-18-induced PMN transmigration were also assessed by immunohistochemistry and confocal laser microscopy.
Statistical analysis. Values are means Ϯ SE. Statistical analysis was performed using Prism 5 software, which verifies normality of data prior to analysis. Comparisons were made using Student's t-test or one-way ANOVA as appropriate. Post hoc analysis was performed with the Student-Newman-Keuls test. To compile the results of several Western blotting experiments, results were normalized to GAPDH values (set at 100%) prior to statistical analysis. Statistical significance was established at P Ͻ 0.05.
RESULTS

IL-18 disrupts tight junctional occludin in colonic Caco-2 monolayers.
The integrity of epithelial junctional complexes upon exposure to IL-18 was first assessed by immunocytochemistry for different components of the tight and adherens junctions.
Control colonic Caco-2 monolayers displayed membrane distribution of claudin-4, claudin-5, and occludin in a characteristic chicken-wire staining pattern (Fig. 1A) . Basolateral treatment with IL-18 (50 ng/ml) for 24 h had no effect on the distribution pattern of either protein. In contrast, apical treatment with IL-18 at the same concentration induced the selective disruption of occludin, while the distribution pattern of claudin-4 and claudin-5 remained essentially unchanged (Fig. 1A) . Unless otherwise mentioned, all further experiments investigating the structural effect of IL-18 on apical junctional complexes were performed with apically treated Caco-2 monolayers.
In an attempt to further characterize the effect of IL-18 on apical junctional complexes and determine if its disruptive effect was limited to occludin, control and apically IL-18-treated cells were stained for the tight junction protein ZO-1 and the adherens junction protein E-cadherin. No differences in the staining pattern of either protein could be detected between groups (Fig. 1B) .
These findings were corroborated by Western blotting analysis; apical treatment with IL-18 induced a significant decrease in occludin ( Fig. 2A) , without affecting the total levels of claudin-4, claudin-5, ZO-1, and E-cadherin (Fig. 2B) . IL-18-induced loss of occludin does not appear to result from changes in occludin transcription, as no changes in occludin mRNA levels could be detected between control and IL-18-treated cells 24 h after treatment (Fig. 2C) .
IL-18 disrupts occludin in a MLCK-and NF-B-dependent manner.
Previous studies demonstrated that IL-1␤, by activating NF-B, disrupts epithelial tight junctions and increases epithelial permeability in Caco-2 monolayers in a MLCKdependent manner (2, 3). On the basis of these observations, we investigated the role of MLCK in IL-18-induced occludin disruption in the present model. Caco-2 monolayers treated with IL-18 showed a significant increase in MLCK protein levels compared with untreated controls (Fig. 3A) . IL-18 also induced an increase in phosphorylated MLC II, indicating an overall increase in MLCK activity (Fig. 3B) . MLC II total levels were not significantly affected by IL-18.
To evaluate if MLCK was directly involved in IL-18-induced occludin disruption, the selective MLCK inhibitor ML9 was used 1 h prior to IL-18 treatment. Immunoblotting Fig. 2 . IL-18 reduces occludin total protein levels in Caco-2 monolayers. Caco-2 cells were treated apically with IL-18 for 24 h and processed for Western blotting and quantitative PCR. Con, control. IL-18 induced a significant decrease in occludin, without affecting total levels of claudin-4, claudin-5, ZO-1, and E-cadherin (A). No changes in occludin mRNA levels could be detected between groups (B). Densitometry data and relative mRNA levels are expressed as %GAPDH (C). Values are means Ϯ SE; n ϭ 6 per group. *P Ͻ 0.05. [Densitometry relative to GAPDH and statistical analysis were performed for all 5 apical junctional complex proteins (data not shown).] (Fig. 4A ) and immunocytochemistry (data not shown) revealed that inhibition of MLCK prevented, at least in part, IL-18-induced loss of occludin. The inhibitor alone had no effect on occludin total levels. The same trend could also be observed by immunocytochemistry (data not shown).
The IL-18 receptor, similar to the IL-1 receptor type I, is known to signal through NF-B to induce the expression of several genes involved in inflammatory responses (1) . In an attempt to determine if NF-B was involved in IL-18-induced disruption of occludin, the NF-B inhibitor BAY 11 was used 1 h prior to IL-18 treatment. Immunoblotting (Fig. 4B ) and immunocytochemistry (data not shown) demonstrated that inhibition of NF-B prevented the loss of occludin in IL-18-treated cells compared with untreated controls. The inhibitor alone had no effect on occludin protein levels.
IL-18-induced occludin disruption does not affect epithelial permeability.
In another set of experiments, we examined the functional outcome of IL-18-induced occludin disruption on epithelial monolayers by assessing the effect of IL-18 on paracellular permeability. Despite the loss of occludin, no concomitant decreases in transepithelial resistance (Fig. 5A) or apical-to-basolateral fluxes of FITC-dextran (Fig. 5B) could be detected between control and IL-18-treated (apically or basolaterally) monolayers. To further verify these observations, apical-to-basolateral translocation of nonpathogenic E. coli was also used as an indicator of transepithelial permeability. Consistent with the previous measurements, apical challenge with IL-18 failed to induce changes in E. coli translocation across Caco-2 monolayers (Fig. 5C ), further indicating intact barrier function. 
IL-18-induced MLCK-dependent disruption of occludin facilitates PMN transmigration across Caco-2 monolayers.
In an attempt to uncover the functional significance of IL-18-induced tight junction alteration, the effect of IL-18 on basolateral-toapical PMN transepithelial migration was assessed. fMLPinduced PMN transmigration was significantly enhanced in IL-18-treated monolayers compared with untreated controls (Fig. 6) . Given the role of MLCK in IL-18-induced occludin disruption, we postulated that MLCK might play a role in PMN migration across IL-18-treated epithelial monolayers. To test this hypothesis, the MLCK inhibitor ML9 was added to monolayers 1 h prior to IL-18 treatment, and PMN transmigration was measured. Inhibition of MLCK significantly reduced IL-18-induced PMN migration across Caco-2 monolayers (Fig. 6 ). The inhibitor alone had no effect on PMN transepithelial movement.
Finally, the role of occludin disruption in IL-18-induced PMN transmigration was reinforced by confocal imaging of occludin during basolateral-to-apical passage of PMNs across Caco-2 monolayers. While control monolayers demonstrated membrane-associated tight junctional occludin and PMNs resting on the basolateral side, IL-18-treated monolayers displayed diffuse occludin staining, in addition to transepithelial migration and apical accumulation of PMNs (Fig. 7) . Consistent with our occludin immunoblot and quantitative PMN transmigration data, inhibition of MLCK by ML9 prevented IL-18-induced occludin mislocalization (at least partially) and increase in PMN migration into the apical compartment (Fig. 7) .
DISCUSSION
Defects in epithelial tight junction structure, function, and regulation have been implicated in the pathophysiology of a variety of GI disorders, including microbial enteritis, celiac disease, and IBD (10, 20, 26, 29, 43, 49) . While proinflammatory mediators such as TNF␣ have been extensively studied for their role in epithelial malfunction in IBD, the effect of IL-18 on epithelial junctional complexes remains unknown. Increased levels of IL-18 have been observed in mucosal samples from CD and UC patients (35, 39, 48) . Remarkably, several reports have demonstrated that immunological neutralization or targeted gene deletion of IL-18 ameliorates the severity of colitis in multiple in vivo models of IBD (25, 54 -56, 59 ) via mechanisms that remain elusive. The present study uncovers a novel mechanism whereby IL-18 selectively disrupts tight junctional occludin to facilitate PMN migration across colonic epithelial monolayers. This may contribute to overt inflammatory responses and tissue damage in IBD and could help explain the beneficial effect of anti-IL-18 therapy in murine models of colitis (25, 54 -56, 59) .
A significant increase in MLCK expression has been observed in intestinal tissue from CD patients, which correlates with the severity of colitis in these individuals (6). Our results indicate that IL-18 induces an increase in MLCK expression and activity in human colonic Caco-2 monolayers and that IL-18-mediated occludin disruption could be prevented by MLCK inhibition. Proinflammatory cytokines, including IL-1␤ and TNF␣, are known to induce tight junction disruption via NF-B-dependent regulation of MLCK expression. Consistent with these observations, the present findings demonstrate that IL-18-induced occludin disruption was also dependent on NF-B signaling.
Unlike proteases that target specific tight junction proteins, MLCK acts in a nonselective manner on tight junction transmembrane components by modulating actinomyosin dynamics (57) . Interestingly, our results demonstrate that IL-18, which activates MLCK, selectively disrupts occludin, without affecting the distribution of claudin-4, claudin-5, ZO-1, or E-cadherin. These observations are consistent with previous studies demonstrating that T-cell activation or direct administration of TNF␣ in mice induces MLCK-dependent disruption of occludin, without affecting the cellular distribution of other components of the tight junction, such as claudin-1, claudin-2, claudin-4, claudin-5, and ZO-1 (11, 12) .
Our Western blot and qPCR data suggest that IL-18 induces occludin degradation, rather than a decrease in its gene expression. Since MLCK is devoid of proteolytic activity, a mechanism downstream of MLC II phosphorylation must be involved in IL-18-induced occludin disruption. It was recently demonstrated that caveolar-mediated endocytosis of occludin follows MLCK activation and is required for TNF␣-induced modulation of tight junction structure and function in vivo (37) . Furthermore, it is hypothesized that internalization of individual tight junction proteins could be a biphasic phenomenon wherein acute/transient inflammatory stimuli may induce selective endocytosis of occludin, while chronic/prolonged stimuli could mediate internalization of occludin along with several claudins (58) . Although this hypothesis has yet to be investigated thoroughly, occludin internalization after MLCK activation may represent an early event in epithelial junction disruptions during IBD. Further research is warranted to evaluate the effect of chronic exposure to IL-18 on the integrity of occludin and other tight junction proteins.
Despite its disruptive effect on occludin, the present findings indicate that IL-18 does not induce an increase in paracellular permeability to small ions, macromolecules, or bacterial translocation in Caco-2 monolayers. These observations parallel those from previous studies showing that occludin-deficient epithelial cells have normal tight junction structure and that occludin-deficient mice demonstrate normal colonic epithelial permeability (51, 52) .
In physiological conditions, opening of tight junctions is required for low-density leukocyte migration across the GI epithelium into the lumen (40, 46) . This process is essential for constant immune surveillance and does not induce lasting changes to epithelial barrier properties (40, 46) . In contrast, high-density transepithelial movement of PMNs was shown to impair barrier function and create multifocal opening in cultured epithelial monolayers (40, 42, 44, 45) . The present findings indicate that, upon IL-18 treatment, occludin disruption facilitates PMN transepithelial migration. This is consistent with previous studies in transfected Madin-Darby canine kidney cells demonstrating that specific domains of occludin are key in modulating PMN migration across epithelial monolayers (21) . Furthermore, our data indicate for the first time that IL-18 facilitates the basolateral-to-apical passage of PMNs across intestinal epithelia via MLCK-dependent disruption of occludin. These results are in keeping with observations from a recent study demonstrating that Toll-like receptor-2-mediated calpain-dependent cleavage of E-cadherin and occludin promotes PMN transmigration across airway epithelia, without compromising barrier function (9) . In addition, a recent study showed that occludin may play a key role in facilitating transepithelial traffic of intraepithelial lymphocytes as well (15) . Together with our findings, these observations underscore that fine changes in epithelial barrier structure, although too subtle to alter paracellular permeability, may be of great physiological significance by accommodating leukocyte transmigration. Further research is warranted to establish the involvement of the IL-18 and/or IL-1 receptor in PMN transmigration through MLCK-dependent modulation of occludin and also to determine if other proinflammatory mediators (e.g., IL-1, IL-33, and TNF␣) could participate in this process.
Consistent with previous findings demonstrating a role for MLCK in PMN transepithelial migration (16) , the present study indicates that inhibition of MLCK prevents IL-18-induced occludin disruption and PMN transmigration across Caco-2 monolayers. Therefore, we propose a model in which IL-18 induces MLCK-dependent disruption of occludin, which in turn facilitates PMN transmigration across intestinal epithelial monolayers, without altering epithelial permeability. In IBD, loss of epithelial barrier function is further exacerbated by the release of cytotoxic antimicrobial products by luminal PMNs, which further amplifies local inflammatory responses, tissue damage, and ulceration (8) . Indeed, during acute bouts of inflammation, infiltration of PMNs into the mucosa correlates with a significant decrease in the expression of several tight and adherens junction proteins, as well as an increase in epithelial permeability (29) . Further research will help establish whether MLCK inhibitors may offer dual therapeutic benefits in the treatment of IBD, as the present study demonstrates that they may act not only on barrier restoration but also on PMN recruitment.
The present findings also uncover a new regulatory role for occludin in epithelial barrier function. The exact functions of occludin in the epithelium remain topics of ongoing debate. Indeed, occludin-deficient mice, although presenting with gastritis and gastric atrophy, do not show enhanced colonic permeability (52) . Yet several studies using different in vitro and in vivo models have established a functional role for occludin in the GI epithelium (7, 23, 38, 41, 53, (61) (62) (63) . Notably, peptides mimicking the occludin extracellular loop domain have been shown to induce tight junction disassembly and loss of epithelial barrier function (5). Furthermore, it was recently demonstrated that overexpression of occludin within the intestinal epithelium protects mice from TNF␣-induced barrier dysfunction and development of diarrhea (37) . This study, along with other reports (11, 62, 64) , indicates that occludin plays a role in epithelial function during pathological conditions as well. Consistent with these observations, the present findings indicate that occludin may play a role in regulating transepithelial migration of inflammatory cells.
In conclusion, the present study demonstrates that IL-18 facilitates PMN transepithelial migration via MLCK-dependent disruption of tight junctional occludin without altering epithelial permeability. These observations may shed new light on our understanding of the pathophysiology of IBD and may help uncover novel therapeutic strategies. Importantly, the findings add to the growing body of evidence demonstrating key regulatory roles for occludin in epithelial tight junctions.
